Taysha Gene Therapies/$TSHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Ticker
$TSHA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
73
ISIN
US8776191061
Website
TSHA Metrics
BasicAdvanced
$556M
-
-$0.33
1.02
-
Price and volume
Market cap
$556M
Beta
1.02
52-week high
$3.24
52-week low
$1.05
Average daily volume
3.2M
Financial strength
Current ratio
5.351
Quick ratio
5.169
Long term debt to equity
108.649
Total debt to equity
111.933
Interest coverage (TTM)
-909.91%
Profitability
EBITDA (TTM)
-82.509
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,201.08%
Operating margin (TTM)
-1,158.80%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-35.91%
Return on equity (TTM)
-159.34%
Valuation
Price to revenue (TTM)
93.092
Price to book
9.65
Price to tangible book (TTM)
9.65
Price to free cash flow (TTM)
-8
Free cash flow yield (TTM)
-12.50%
Free cash flow per share (TTM)
-32.37%
Growth
Revenue change (TTM)
-48.97%
Earnings per share change (TTM)
-55.22%
3-year earnings per share growth (CAGR)
-59.64%
What the Analysts think about TSHA
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
Bulls say / Bears say
Taysha's lead candidate, TSHA-102, has shown promising safety and efficacy results in early-stage clinical trials for Rett syndrome, with the Independent Data Monitoring Committee approving dose escalation ahead of schedule, potentially expediting its development timeline. (Investing.com)
The company has strengthened its financial position by raising $76.8 million through a public follow-on offering, extending its cash runway into the fourth quarter of 2026, providing ample resources to advance its clinical programs. (Investing.com)
Analysts have a consensus 'Strong Buy' rating for Taysha Gene Therapies, with an average price target of $8.20, indicating a potential upside of approximately 238.84% from the current stock price. (StockAnalysis.com)
Despite early promising results, TSHA-102 has been tested in a limited number of patients, making it challenging to draw definitive conclusions about its efficacy and safety across a broader population, which may impact investor confidence. (Investing.com)
The regulatory approval process for TSHA-102 faces potential hurdles, including the FDA's preference for randomized controlled trials over single-arm studies with natural history comparisons, which could delay approval timelines. (Investing.com)
A recent analysis initiated coverage on Taysha with a 'Sell' rating, citing high clinical risk and a potentially narrow market opportunity for its lead Rett syndrome program, suggesting that the current valuation may not justify the significant risks involved. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TSHA Financial Performance
Revenues and expenses
TSHA Earnings Performance
Company profitability
TSHA News
AllArticlesVideos
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Taysha Gene Therapies stock?
Taysha Gene Therapies (TSHA) has a market cap of $556M as of July 18, 2025.
What is the P/E ratio for Taysha Gene Therapies stock?
The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of July 18, 2025.
Does Taysha Gene Therapies stock pay dividends?
No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Taysha Gene Therapies dividend payment date?
Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.